CellaVision AB: Interim report January - March 2013
(Thomson Reuters ONE) -
More sales channels increase our growth opportunities but the year got off to a
weak start
January 1 - March 31, 2013
* Net sales were SEK 33.8 million (40.4).
* Operating profit was SEK -0.7 million (5.4).
* Profit before tax was SEK -1.5 million (4.4).
* Earnings per share were SEK -0.06 (0.11).
* Cash and cash equivalents at the close of the quarter were SEK 52.5 million
(56.5).
* CellaVision signs an agreement with one more distribution partner in Europe
- Abbott.
* New product for quality assurance launched - CellaVision® Proficiency
Software.
Significant events after the period close
* CellaVision and Beckman Coulter increased their cooperation by adding EMEA
to their global distribution agreement. The agreement entered into force on
April 8, 2013.
* On April 16 CellaVision and Sysmex published the news of a jointly developed
product, the DI-60, for laboratories in hematology. CellaVision's digital
image analysis technology has been integrated with Sysmex cell counters and
sample preparation instruments.
* On April 19 Magnus Blixt was appointed new CFO, taking up his position on
May 2, 2013.
Key ratios
(SEK million) Jan-March 2013 Jan-March 2012 Full year
2012
Net sales 33.8 40.4 169.5
Gross profit or loss 22.0 27.1 110.1
Operating profit -0.7 5.4 20.7
Operating margin, % Neg. 13.4 12.2
Profit/loss before tax -1.5 4.4 18.6
Cash flow for the period 6.3 -0.3 -10.6
Comments by CellaVision's CEO Yvonne Mårtensson:
"The subdued demand for medical devices we experienced at the end of 2012 has
continued into 2013. In the year's first quarter our sales were lower in our
main markets, Europe and North America, and we report negative earnings.
Fortunately enough, our sales are strong in the Asia & Pacific region, which is
a result of determined market penetration in the region. The region is an
important growth market for us.
In 2013 several business transactions have taken place that are of very great
significance for CellaVision's future development. Siemens started selling
globally and received its first order in Europe. In Europe we broadened our
sales channels at the same time by signing agreements with Beckman Coulter and
Abbott. In most geographical markets we now cooperate with four of the five
major players, which increases CellaVision's visibility and growth potential.
For the first time we are integrating our world-leading technology with a
partner's product. The product is the result of a long-standing sound
partnership with Sysmex but also a natural development of the product offer to
the hematology market, in which automation is an important factor behind
increased effectiveness. The DI-60 will keep CellaVision at the leading edge of
its area of technology. As part of our cost effectiveness strategy the product
was developed on our primary hardware platform, CellaVision DM1200.
Interest in our products and our position in the market has never been stronger.
However, the continuing weak world economy is delaying the hospital
laboratories' purchases of equipment which impacts on our distributors' demand.
Uncertainty in the market affects us and we expect lower income and negative
earnings also in the second quarter. Looking ahead, I look forward with
confidence to the results of our new products and broad distribution channels."
Questions concerning the report can be addressed to:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82. Email: yvonne.martensson(at)cellavision.se
Sven-Åke Henningsson, Acting CFO, CellaVision AB
Tel: +46 705 93 43 81. Email: ir(at)cellavision.se
CellaVision AB: Interim report January-March 2013:
http://hugin.info/132164/R/1695795/558202.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1695795]
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2013 - 14:01 Uhr
Sprache: Deutsch
News-ID 252456
Anzahl Zeichen: 5075
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB: Interim report January - March 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
